41st Annual Meeting of the American-Society-of-Clinical-Oncology Conference

related documents

• A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma.  Conference Paper
• A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCICCTG IND. 154.  Conference Paper
• A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC).  Conference Paper
• A phase II study of UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A Princess Margaret Phase II Consortium Trial  Conference Paper
• A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs).  Conference Paper
• A study of surveillance mammography (SM) of the contralateral breast (CLB) following total mastectomy (TM) for breast cancer (BC).  Conference Paper
• ABREAST: A new global registry of adjuvant strategies in patients with early stage breast cancer.  Conference Paper
• Determinants of preferences for starting extended adjuvant letrozole (L) in postmenopausal women following five years of tamoxifen.  Conference Paper
• Dose reduced first-line capecitabine monotherapy in older and less fit patients with advanced colorectal cancer (ACRC)  Conference Paper
• Evaluation of responsiveness to change to psychosocial group therapy (PGT) and to the process of dying of psychosocial and quality of life (QOL) measures.  Conference Paper
• HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial.  Conference Paper
• Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents  Conference Paper
• Natural history of rising serum PSA in men with castrate nonmetastatic prostate cancer.  Conference Paper
• Phase I-II study of DaICM-P [daily dalteparin (Dal), cyclophosphamide (C) and prednisone (P) and bi-weekly methotrexate (M)] as therapy for metastatic breast cancer (MBC).  Conference Paper
• Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors.  Conference Paper
• Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the princess margaret hospital [PMH] phase II consortium.  Conference Paper
• Phase II study of oblimersen sodium and rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma.  Conference Paper
• Pre-radiation R115777 in patients with newly diagnosed glioblastoma multiforme and residual enhancing disease  Conference Paper
• Predictive value of eTag dimerization assay in patients with metastatic colorectal cancer treated with erlotinib.  Conference Paper
• Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC).  Conference Paper
• Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC).  Conference Paper
• S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results  Conference Paper
• S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results.  Conference Paper
• Subgroup analysis of a phase III trial of doxorubicin vs doxorubicin plus tesmilifene in advanced breast cancer (ABC): Tesmilifene survival benefit focused on patients with more aggressive disease.  Conference Paper
• Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome.  Conference Paper
• The effect of doxycycline on bone turnover and tumor markers in breast cancer (BC) patients with skeletal metastases.  Conference Paper
• The effect of zoledronic acid (Zol) dose and infusion rate on pharmacolkinetics (PK), pharmacodynamics (PD), and renal function in patients (pts) with multiple myeloma (MM) or prostate cancer (PC) and bone metastases.  Conference Paper
• The impact and perception of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of novel anticancer agents.  Conference Paper
• The prognostic effect of lipids on early-stage breast cancer (BC) outcome.  Conference Paper
• What are the supportive care service needs of recently diagnosed cancer patients? Results of a population based study  Conference Paper
• Willingness of older people with cancer to participate in cancer clinical trials is not a barrier to accrual.  Conference Paper